Rationale and design of XAMOS: Noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 363-370

  Turpie, Alexander G G ^a   Schmidt, André C ^b   Kreutz, Reinhold ^c   Lassen, Michael R ^d   Jamal, Waheed ^b   Mantovani, Lorenzo ^e   Haas, Sylvia ^f  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b BAYER PHARMA AG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Effectiveness; Oral anticoagulation; Rivaroxaban; Venous thromboembolism

Indexed keywords

ENOXAPARIN; RIVAROXABAN; ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADVERSE OUTCOME; ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DATA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RESEARCH; HIP SURGERY; HUMAN; KNEE SURGERY; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTOPERATIVE CARE; SAMPLE SIZE; STUDY DESIGN; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; BLEEDING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; HIP; KNEE; METHODOLOGY; MULTICENTER STUDY; ORTHOPEDIC SURGERY; REGISTER; TIME; TREATMENT OUTCOME;

ANTICOAGULANTS; HEMORRHAGE; HIP JOINT; HUMANS; KNEE JOINT; MORPHOLINES; ORTHOPEDIC PROCEDURES; REGISTRIES; RESEARCH DESIGN; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84867676333     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S30064     Document Type: Article

References (28)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):338S-400S.
2. Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br. 2006;88(3):386-391.
3. Seagroatt V, Tan HS, Goldacre M, Bulstrode C, Nugent I, Gill L. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ. 1991;303(6815):1431-1435.
4. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl): 381S-453S.
5. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39.
6. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007;356(25):2653-2655.
7. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79(1):1-7.
8. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335.
9. Elalamy I, Tribout B. Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal. J Thromb Haemost. 2008;6(7):1242-1243.
10. Spyropoulos AC, Magnuson S, Koh SK. The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes. Ther Clin Risk Manag. 2008;4(3):653-657.
11. Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost. 2004;2(7):1058-1070.
12. Mesko JW, Brand RA, Iorio R, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. J Arthroplasty. 2001;16(6):679-688.
13. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326-331.
14. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000;82-A(7):929-938.
15. Asnis PD, Gardner MJ, Ranawat A, Leitzes AH, Peterson MG, Bass AR. The effectiveness of warfarin dosing from a nomogram compared with house staff dosing. J Arthroplasty. 2007;22(2):213-218.
16. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412-421.
17. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880.
18. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.
19. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet. 2009;373(9676):1673-1680.
20. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.
21. Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009;91(5):636-644.
22. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573-1579.
23. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
24. EMEA. Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and postoperative venous thromboembolic risk. 2007. Available from: http://www.emea.europa.eu/pdfs/human/ewp/70798en_fin.pdf. Accessed May 26, 2009.
25. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160(7):967-973.
26. Brown ML, Gersh BJ, Holmes DR, Bailey KR, Sundt TM III. From randomized trials to registry studies: translating data into clinical information. Nat Clin Pract Cardiovasc Med. 2008;5(10):613-620.
27. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther. 2007;82(2):143-156.
28. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. New York: Raven Press; 1984.